Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil

Claudio De Felice, Cinzia Signorini, Thierry Durand, Lucia Ciccoli, Silvia Leoncini, Maurizio D'Esposito, Stefania Filosa, Camille Oger, Alexandre Guy, Valérie Bultel-Poncé, Jean Marie Galano, Alessandra Pecorelli, Laura De Felice, Giuseppe Valacchi, Joussef Hayek

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Evidence of enhanced oxidative stress (O.S.) and lipid peroxidation has been reported in patients with Rett syndrome (RTT), a relatively rare neurodevelopmental disorder progressing in 4-stages, and mainly caused by loss-of-function mutations in the methyl-CpG-binding protein 2. No effective therapy for preventing or arresting the neurologic regression in the disease in its various clinical presentations is available. Based on our prior evidence of enhanced O.S. and lipid peroxidation in RTT patients, herein we tested the possible therapeutic effects of ω-3 polyunsaturated fatty acids (ω-3 PUFAs), known antioxidants with multiple effects, on the clinical symptoms and O.S. biomarkers in the earliest stage of RTT. A total of 20 patients in stage I were randomized (n = 10 subjects per arm) to either oral supplementation with ω-3 PUFAs-containing fish oil (DHA: 72.9 ± 8.1 mg/ kg b.w./day; EPA: 117.1 ± 13.1 mg/kg b.w./day; total ω-3 PUFAs: 246.0 ± 27.5 mg/kg b.w./day) for 6 months or no treatment. Primary outcomes were potential changes in clinical symptoms, with secondary outcomes including variations for five O.S. markers in plasma and/or erythrocytes (nonprotein bound iron, F2-dihomo-isoprostanes, F3-isoprostanes, F4-neuroprostanes, and F2-isoprostanes). A significant reduction in the clinical severity (in particular, motor-related signs, nonverbal communication deficits, and breathing abnormalities) together with a significant decrease in all the examined O.S. markers was observed in the ω-3 PUFAs supplemented patients, whereas no significant changes were evidenced in the untreated group. For the first time, these findings strongly suggest that a dietary intervention in this genetic disease at an early stage of its natural history can lead to a partial clinical and biochemical rescue.

Original languageEnglish
Pages (from-to)447-458
Number of pages12
JournalGenes and Nutrition
Volume7
Issue number3
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Rett Syndrome
Unsaturated Fatty Acids
Oils
Oxidative Stress
F2-Isoprostanes
Lipid Peroxidation
Neuroprostanes
Methyl-CpG-Binding Protein 2
Nonverbal Communication
Isoprostanes
Inborn Genetic Diseases
Fish Oils
Therapeutic Uses
Natural History
Nervous System
Respiration
Iron
Antioxidants
Erythrocytes
Biomarkers

Keywords

  • ω-3 polyunsaturated fatty acids
  • Antioxidants
  • Isoprostanes
  • MeCP2
  • Nonprotein bound iron
  • Oxidative Stress
  • Rett syndrome

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Genetics

Cite this

De Felice, C., Signorini, C., Durand, T., Ciccoli, L., Leoncini, S., D'Esposito, M., ... Hayek, J. (2012). Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes and Nutrition, 7(3), 447-458. https://doi.org/10.1007/s12263-012-0285-7

Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. / De Felice, Claudio; Signorini, Cinzia; Durand, Thierry; Ciccoli, Lucia; Leoncini, Silvia; D'Esposito, Maurizio; Filosa, Stefania; Oger, Camille; Guy, Alexandre; Bultel-Poncé, Valérie; Galano, Jean Marie; Pecorelli, Alessandra; De Felice, Laura; Valacchi, Giuseppe; Hayek, Joussef.

In: Genes and Nutrition, Vol. 7, No. 3, 07.2012, p. 447-458.

Research output: Contribution to journalArticle

De Felice, C, Signorini, C, Durand, T, Ciccoli, L, Leoncini, S, D'Esposito, M, Filosa, S, Oger, C, Guy, A, Bultel-Poncé, V, Galano, JM, Pecorelli, A, De Felice, L, Valacchi, G & Hayek, J 2012, 'Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil', Genes and Nutrition, vol. 7, no. 3, pp. 447-458. https://doi.org/10.1007/s12263-012-0285-7
De Felice, Claudio ; Signorini, Cinzia ; Durand, Thierry ; Ciccoli, Lucia ; Leoncini, Silvia ; D'Esposito, Maurizio ; Filosa, Stefania ; Oger, Camille ; Guy, Alexandre ; Bultel-Poncé, Valérie ; Galano, Jean Marie ; Pecorelli, Alessandra ; De Felice, Laura ; Valacchi, Giuseppe ; Hayek, Joussef. / Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. In: Genes and Nutrition. 2012 ; Vol. 7, No. 3. pp. 447-458.
@article{4cbf776937af4487bfe0eb427c8f6a2f,
title = "Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil",
abstract = "Evidence of enhanced oxidative stress (O.S.) and lipid peroxidation has been reported in patients with Rett syndrome (RTT), a relatively rare neurodevelopmental disorder progressing in 4-stages, and mainly caused by loss-of-function mutations in the methyl-CpG-binding protein 2. No effective therapy for preventing or arresting the neurologic regression in the disease in its various clinical presentations is available. Based on our prior evidence of enhanced O.S. and lipid peroxidation in RTT patients, herein we tested the possible therapeutic effects of ω-3 polyunsaturated fatty acids (ω-3 PUFAs), known antioxidants with multiple effects, on the clinical symptoms and O.S. biomarkers in the earliest stage of RTT. A total of 20 patients in stage I were randomized (n = 10 subjects per arm) to either oral supplementation with ω-3 PUFAs-containing fish oil (DHA: 72.9 ± 8.1 mg/ kg b.w./day; EPA: 117.1 ± 13.1 mg/kg b.w./day; total ω-3 PUFAs: 246.0 ± 27.5 mg/kg b.w./day) for 6 months or no treatment. Primary outcomes were potential changes in clinical symptoms, with secondary outcomes including variations for five O.S. markers in plasma and/or erythrocytes (nonprotein bound iron, F2-dihomo-isoprostanes, F3-isoprostanes, F4-neuroprostanes, and F2-isoprostanes). A significant reduction in the clinical severity (in particular, motor-related signs, nonverbal communication deficits, and breathing abnormalities) together with a significant decrease in all the examined O.S. markers was observed in the ω-3 PUFAs supplemented patients, whereas no significant changes were evidenced in the untreated group. For the first time, these findings strongly suggest that a dietary intervention in this genetic disease at an early stage of its natural history can lead to a partial clinical and biochemical rescue.",
keywords = "ω-3 polyunsaturated fatty acids, Antioxidants, Isoprostanes, MeCP2, Nonprotein bound iron, Oxidative Stress, Rett syndrome",
author = "{De Felice}, Claudio and Cinzia Signorini and Thierry Durand and Lucia Ciccoli and Silvia Leoncini and Maurizio D'Esposito and Stefania Filosa and Camille Oger and Alexandre Guy and Val{\'e}rie Bultel-Ponc{\'e} and Galano, {Jean Marie} and Alessandra Pecorelli and {De Felice}, Laura and Giuseppe Valacchi and Joussef Hayek",
year = "2012",
month = "7",
doi = "10.1007/s12263-012-0285-7",
language = "English",
volume = "7",
pages = "447--458",
journal = "Genes and Nutrition",
issn = "1555-8932",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil

AU - De Felice, Claudio

AU - Signorini, Cinzia

AU - Durand, Thierry

AU - Ciccoli, Lucia

AU - Leoncini, Silvia

AU - D'Esposito, Maurizio

AU - Filosa, Stefania

AU - Oger, Camille

AU - Guy, Alexandre

AU - Bultel-Poncé, Valérie

AU - Galano, Jean Marie

AU - Pecorelli, Alessandra

AU - De Felice, Laura

AU - Valacchi, Giuseppe

AU - Hayek, Joussef

PY - 2012/7

Y1 - 2012/7

N2 - Evidence of enhanced oxidative stress (O.S.) and lipid peroxidation has been reported in patients with Rett syndrome (RTT), a relatively rare neurodevelopmental disorder progressing in 4-stages, and mainly caused by loss-of-function mutations in the methyl-CpG-binding protein 2. No effective therapy for preventing or arresting the neurologic regression in the disease in its various clinical presentations is available. Based on our prior evidence of enhanced O.S. and lipid peroxidation in RTT patients, herein we tested the possible therapeutic effects of ω-3 polyunsaturated fatty acids (ω-3 PUFAs), known antioxidants with multiple effects, on the clinical symptoms and O.S. biomarkers in the earliest stage of RTT. A total of 20 patients in stage I were randomized (n = 10 subjects per arm) to either oral supplementation with ω-3 PUFAs-containing fish oil (DHA: 72.9 ± 8.1 mg/ kg b.w./day; EPA: 117.1 ± 13.1 mg/kg b.w./day; total ω-3 PUFAs: 246.0 ± 27.5 mg/kg b.w./day) for 6 months or no treatment. Primary outcomes were potential changes in clinical symptoms, with secondary outcomes including variations for five O.S. markers in plasma and/or erythrocytes (nonprotein bound iron, F2-dihomo-isoprostanes, F3-isoprostanes, F4-neuroprostanes, and F2-isoprostanes). A significant reduction in the clinical severity (in particular, motor-related signs, nonverbal communication deficits, and breathing abnormalities) together with a significant decrease in all the examined O.S. markers was observed in the ω-3 PUFAs supplemented patients, whereas no significant changes were evidenced in the untreated group. For the first time, these findings strongly suggest that a dietary intervention in this genetic disease at an early stage of its natural history can lead to a partial clinical and biochemical rescue.

AB - Evidence of enhanced oxidative stress (O.S.) and lipid peroxidation has been reported in patients with Rett syndrome (RTT), a relatively rare neurodevelopmental disorder progressing in 4-stages, and mainly caused by loss-of-function mutations in the methyl-CpG-binding protein 2. No effective therapy for preventing or arresting the neurologic regression in the disease in its various clinical presentations is available. Based on our prior evidence of enhanced O.S. and lipid peroxidation in RTT patients, herein we tested the possible therapeutic effects of ω-3 polyunsaturated fatty acids (ω-3 PUFAs), known antioxidants with multiple effects, on the clinical symptoms and O.S. biomarkers in the earliest stage of RTT. A total of 20 patients in stage I were randomized (n = 10 subjects per arm) to either oral supplementation with ω-3 PUFAs-containing fish oil (DHA: 72.9 ± 8.1 mg/ kg b.w./day; EPA: 117.1 ± 13.1 mg/kg b.w./day; total ω-3 PUFAs: 246.0 ± 27.5 mg/kg b.w./day) for 6 months or no treatment. Primary outcomes were potential changes in clinical symptoms, with secondary outcomes including variations for five O.S. markers in plasma and/or erythrocytes (nonprotein bound iron, F2-dihomo-isoprostanes, F3-isoprostanes, F4-neuroprostanes, and F2-isoprostanes). A significant reduction in the clinical severity (in particular, motor-related signs, nonverbal communication deficits, and breathing abnormalities) together with a significant decrease in all the examined O.S. markers was observed in the ω-3 PUFAs supplemented patients, whereas no significant changes were evidenced in the untreated group. For the first time, these findings strongly suggest that a dietary intervention in this genetic disease at an early stage of its natural history can lead to a partial clinical and biochemical rescue.

KW - ω-3 polyunsaturated fatty acids

KW - Antioxidants

KW - Isoprostanes

KW - MeCP2

KW - Nonprotein bound iron

KW - Oxidative Stress

KW - Rett syndrome

UR - http://www.scopus.com/inward/record.url?scp=84866006373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866006373&partnerID=8YFLogxK

U2 - 10.1007/s12263-012-0285-7

DO - 10.1007/s12263-012-0285-7

M3 - Article

VL - 7

SP - 447

EP - 458

JO - Genes and Nutrition

JF - Genes and Nutrition

SN - 1555-8932

IS - 3

ER -